Deciphering the cell-cell interactions and therapeutic targets in P53-mutant adenocarcinoma at a single-cell resolution

The Icahn School of Medicine at Mount Sinai will receive $422,500 from the Department of the Army Medical Command under a two-year Project Grant award to decipher cell-cell interactions and therapeutic targets in p53-mutant adenocarcinoma at single-cell resolution. The research funded under this award, which runs from September 1, 2022 to August 31, 2024, directly supports the Military Medical Research and Development program administered by the Department of the Army Medical Command. This program aims to transform military and public health through innovative medical research solutions for battlefield injuries and investigations into new medical treatments. The Icahn School of Medicine will leverage the $422.5k in funding to advance understanding of cell-cell communication patterns and potential therapeutic vulnerabilities at the single-cell level in cancers with p53 mutations, a gene often disrupted in aggressive tumors. Insights from this research could ultimately help improve outcomes for cancer patients.